EPCAM and prostate carcinoma: These internal structures are subsequently functionalized with anti-EpCAM antibodies to ensure the specific capture of EpCAM-positive human cancer cell lines, including MCF-7 breast cancer, SW480 colon cancer, and PC3 prostate cancer.